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A B S T R A C T
The influence of drug-receptor binding kinetics has often been overlooked during the development of new
therapeutics that target G protein-coupled receptors (GPCRs). Over the last decade there has been a growing
understanding that an in-depth knowledge of binding kinetics at GPCRs is required to successfully target this
class of proteins. Ligand binding to a GPCR is often not a simple single step process with ligand freely diffusing in
solution. This review will discuss the experiments and equations that are commonly used to measure binding
kinetics and how factors such as allosteric regulation, rebinding and ligand interaction with the plasma mem-
brane may influence these measurements. We will then consider the molecular characteristics of a ligand and if
these can be linked to association and dissociation rates.
1. Introduction
The phrase ‘Corpora non agunt nisi fixata’ or ‘a drug will only act
when bound to its target’ is perhaps the most well-known and influ-
ential phrase within the field of drug-receptor pharmacology and was
coined by the renowned German pharmacologist Dr Paul Ehrlich.
Knowing the life-time of the interaction of a drug with its target re-
ceptor through measuring its kinetic parameters, is therefore crucial to
understanding the full pharmacological effect of a drug and to progress
knowledge of its mode of action. A better understanding of the effect of
kinetic parameters on drug action is slowly emerging and suggests that
the association rate of a ligand with its receptor (kon) may be just as
important as the length of time that the ligand is bound (residence time
(1/koff)) in dictating the action of drugs in vivo.
One of the most successfully targeted class of receptors for the de-
velopment of pharmaceuticals are the cell surface G protein-coupled
receptors (GPCRs) with over 26% of currently approved pharmaceu-
ticals having a GPCR as its main physiological target (Garland, 2013).
However there is still considerable interest in the development of new
compounds that target GPCRs as those currently marketed only target
10% of the GPCR superfamily. Many of these remaining GPCRs have
been implicated in a variety of diseases and there have been many at-
tempts to generate compounds that act at these receptors but many
have failed in clinical trials often due to a lack of efficacy (Kola and
Landis, 2004; Waring et al., 2015). The influence of drug-receptor
binding kinetics has often been overlooked during the development of
new therapeutics but there is a growing understanding that an in-depth
knowledge of binding kinetics at GPCRs is required to successfully
target this class of proteins (Copeland, 2016; Schuetz et al., 2017). This
review will discuss the experiments and equations that are commonly
used to measure binding kinetics and the factors that may influence
these measurements. We will then consider the molecular character-
istics of a ligand and if these can be linked to association and dis-
sociation rates.
2. Equilibrium affinity, association and dissociation rates
The equilibrium dissociation constant (Kd) is an important phar-
macological parameter which describes the concentration of a drug
required to occupy 50% of its target receptors at equilibrium. This value
was traditionally considered fundamental to understanding structure/
function relationships which in turn has enabled more efficient drug
design. Kd is often determined directly from saturation type ligand-
binding experiments, where increasing amounts of a labelled ligand are
added and the levels of bound ligand are measured (Fig. 1). From these
experiments, Kd is defined as the concentration of ligand producing half
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maximal specific binding (Fig. 1), once non-specific binding has been
taken into account. Kd by definition is an equilibrium parameter and
when measured in a closed system, such as is the case for simple
binding reactions, the concentration of reactants reaches the point that
the forward and reverse reactions are in balance. This means that Kd is
only half the story as it is a composite of two kinetic parameters, the
association rate constant (kon) and dissociation rate constant (koff) of a
ligand and is therefore defined as a ratio of these rate constants
(Kd= koff/kon, Fig. 1).
The dissociation rate constant, koff, describes the dissociation of a
single species and is therefore a unimolecular or first order rate con-
stant and describes the rate of drug-target dissociation (Fig. 1). koff is
independent of the local concentration of free drug and is entirely de-
pendent on specific interactions between the drug and its target which
in the case of GPCRs is often a binding pocket. As koff is independent of
ligand concentration it is expressed in units of s−1 (or min−1).
The association rate constant, kon is a bimolecular or second order
rate constant as it describes the rate at which two molecules (the drug
and the receptor) bind to each other, estimating the rate of drug-target
complex formation. Binding reactions are said to be either diffusion
limited, which describes a process so fast that the reactants need only
collide with one another for binding to occur, or encounter limited
indicating that before a reaction can occur the reactants must undergo
some degree of reorganisation, which may be reorientation and/or
desolvation. As a consequence kon cannot be greater than the diffusion
limit of 1×109M−1 s−1 which represents the maximum rate at which
two molecules can move through an aqueous environment and even-
tually collide (Alberty and Hammes, 1958). When kon approaches the
diffusion limit essentially all encounters of unbound receptor and
molecule involved result in successful binding.
As shown in Fig. 1, the measured association phase is termed kon(obs)
rather than kon. kon(obs) is the observed rate of drug association and is
composite of both association and dissociation rates. In addition,
kon(obs) is highly dependent upon drug concentration; a higher con-
centration of ligand will result in a faster kon(obs) (Fig. 2). Therefore, kon
is equal to (kon(obs)-koff)/[ligand] and is expressed as M−1 s−1 (or M−1
min−1).
3. How are kinetics measured at a GPCR?
3.1. Radioligand binding assays
Traditionally the kinetics of drugs have been studied directly using
radiolabelled forms of the compounds (Insel and Stoolman, 1978;
Bürgisser et al., 1981; García-Sevilla et al., 1981). In such experiments,
membranes containing the receptor of interest are incubated with in-
creasing concentrations of radioligand in the presence and absence of
an excess of competitor used to define non-specific binding and the
levels of binding monitored at different time points (Fig. 2). The re-
sulting data can be fitted to equations to derive the kon and koff rate
constants of the radioligand. The dissociation rate can be monitored by
pre-incubating the receptors with radioligand, with the dissociation
phase being initiated by adding an excess of unlabelled competitor or
through the process of ‘infinite’ tracer dilution (Fig. 1). These experi-
ments are likely to produce the most direct information about a drug's
association and dissociation rates however they are not without their
problems especially when we consider that some drugs based on en-
dogenous ligands such as monoamines have low affinities for their
Fig. 1. Simulated saturation and kinetic binding
curves. Saturation and kinetic binding curves were
simulated in GraphPad prism assuming R + L ⇋ RL
using the one site: total and non-specific binding
equation (A) or association then dissociation equa-
tion (B) for a ligand with a Kd of 5nM (A) or 50nM
(B). For (A), the specific binding (squares) Bmax was
set to 100 and Kd to 5 nM and the non-specific
binding (triangles) set to a slope of 0.25. For (B) the
kon was set to 1× 106M−1min−1 and koff to 0.05
min−1, the concentration of ligand to 50 nM and the
BMAX to 150, which results in a Kd of 50 nM. The
association phase of the kinetic binding curve is
termed kon(obs) and is defined as kon = (kon(obs)-koff)/
[ligand].
Fig. 2. Simulated association kinetics binding
curves. Typical association kinetic binding curves
were generated in GraphPad Prism assuming R + L
⇋ RL. The equation ‘two or more concentrations of
hot ligand’ was used with tracer concentrations fixed
at 10, 30, 50 and 100 nM. The koff value was set to
0.05 min−1 and kon to 1×106M−1min−1 and Bmax
set to 150. This is an example of the data obtained in
association kinetic experiments with a ligand with a
Kd of 50 nM.
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orthosteric binding site relative to their affinities for non-specific sites
that can result in a small window of specific binding (Auberson et al.,
2016; Laruelle et al., 2003). Dissociation experiments based on addition
of a high concentration of a competing ligand also assume that there is
no allosteric component to the ligand-receptor binding interactions.
This has been demonstrated for receptors such as the chemokine re-
ceptors, CCR2 and CCR5, and the adenosine A3 receptor, whereby the
presence of an unlabelled ligand changes the dissociation constants of
labelled ligands under infinite dilution conditions (Springael et al.,
2006).
Another problem with the above described procedures is that every
compound of interest must be custom synthesised and labelled with a
radioisotope which is cost and time prohibitive, and therefore restricts
the number of compounds which can be readily tested. An alternative
method is to use a single radioligand with high affinity and selectivity
for the receptor and utilise the equations provided by Motulsky and
Mahan allowing the kinetics of an unlabelled ligand in competition
with the radioligand to be determined (Motulsky and Mahan, 1984,
Fig. 3). This method has been applied successfully by ourselves and
others to determine the kinetics of both antagonists (Dowling and
Charlton, 2006; Stoddart et al., 2018, Sykes et al., 2014a) and agonists
(Guo et al., 2012; Sykes et al., 2009; Sykes et al., 2012a) acting at a
variety of GPCRs and more recently at non-GPCR targets (Yu et al.,
2015). Alternatively, multistep washout experiments (see Vauquelin
and Van Liefde., 2012 for a comprehensive review) have been em-
ployed to compare the dissociation rates of unlabelled antipsychotics
(Leysen and Gommeren, 1984; Tresadern et al., 2011) and mu opoid
receptor specific ligands (Ilien et al., 1988) although this method is
qualitative and only allows relative differences in dissociation rates to
be approximated.
When used with high affinity ligands, these type of experiments
provide a high degree of sensitivity, nonetheless the use of radioactive
ligands as tracers presents a number of challenges. Most compelling is
that they cannot be read continuously; for every time point required to
generate kinetic data a separate experimental condition needs to be
prepared. In addition, classic radioactive binding assays cannot be
performed in a homogeneous format as the bound fraction of radi-
oligand needs to be separated from the free fraction which is usually
achieved by filtration to trap the membranes onto filter paper or by
multiple wash steps when using cells grown in mono-layer. Another
major drawback with radioactive probes is their hazardous nature
which can be restrictive in terms of safe exposure levels, and impose
expensive radioactive waste disposal procedures and delimitation of
working areas. This makes these assays more difficult to perform in a
high throughput screening mode and therefore less attractive to im-
plement in a drug discovery setting. Recently, bead-based scintillation
proximity assays have been developed specifically to measure binding
kinetics (Xia et al., 2016) under homogeneous conditions. However,
this does not overcome the safety issues associated with the use of
radioligands. In addition, such assays suffer from bead settling which
can lead to inaccurate estimates of binding at the very early time points
with these time points being often critical for accurate estimations of
unlabelled compound kinetic parameters.
3.2. Fluorescence based methods
The emergence of fluorescence-based methods offers an alternative
to radioactive binding assays and represents a potentially higher-
throughput approach to assess unlabelled ligand kinetics. Inherently,
the fluorescent probes themselves are safer making assays easier to
implement plus the costs associated with waste disposal compared to
radiometric assays is minimal. High affinity fluorescent tracers have
now been designed and synthesized for numerous receptors and are
now readily available from an ever increasing number of commercial
suppliers (Ciruela et al., 2014; Vernall et al., 2014). It is important to
note that the addition of a fluorophore to a ligand will increase its
molecular weight and can change its physicochemical properties (e.g.
hydrophobicity). This may increase steric hindrance resulting in sig-
nificantly altered pharmacological properties (Vernall et al., 2014).
However, even a modest reduction in affinity need not reduce the ef-
fectiveness of the ligand in pharmacological binding studies provided it
remains specific for the intended target protein. Such reductions in
affinity may actually provide a more viable tracer for high throughput
screening kinetic studies (which ultimately rely on miniaturisation),
since they are less prone to tracer depletion, a potential problem in the
smaller assay volumes routinely employed (Carter et al., 2007).
Direct measurement of the binding of fluorescent ligands to a re-
ceptor is possible using confocal microscopy and this has been suc-
cessfully applied to measure the kinetics of ligands binding to the
adenosine A1 and A3 (May et al., 2010) and the β1-adrenoceptor
(Gherbi et al., 2015). These techniques are very sensitive and provide a
high degree of resolution but are time consuming. Higher throughput
methods have been developed to measure levels of fluorescent ligand in
a plate reader-based format which are well suited to measure equili-
brium binding (Arruda et al., 2017) but the signal-to-noise ratio is often
too small to accurately determine binding kinetics due to high non-
specific binding of the ligands (Stoddart et al., 2015a). This lack of
resolution can be overcome through the use of resonance energy
transfer (RET) based methods as a signal is only observed when the
fluorescent ligand and energy source (fluorescent or bioluminescent
protein) are in close proximity (< 10 nm; Fig. 4). Both time-resolved
fluorescence- (TR-FRET) and bioluminescence- (BRET) resonance en-
ergy transfer techniques have been applied to successfully monitor the
real time kinetics of ligand binding to GPCRs (Schiele et al., 2015;
Stoddart et al., 2018).
The TR-FRET method utilizes self labelling proteins, such as SNAP,
CLIP, ACP (all New England Biolabs respectively) or Halo (Promega
Corporation)-tagged receptors which are then labelled with a substrate
carrying a lanthanide cryptate such as terbium (Cisbio Bioassays) which
forms a covalent bond. FRET detection then occurs following the
transfer of energy from the terbium donor, to an acceptor fluorophore
attached to a ligand selective for the receptor of interest (Schiele et al.,
Fig. 3. Simulated competition association
binding curves fitted using the Motulsky and
Mahan equation to determine the kinetics of
unlabelled ligands. Typical kinetic tracer profile
observed with an unlabelled ligand with similar ki-
netics to the labelled ligand A or with a slower koff in
comparison to the labelled ligand B. Simulations
were generated in GraphPad Prism using the
Motulsky and Mahan equation. For both A and B the
concentration of the labelled ligand (L) was set to
50 nM, kon (K1) to 1× 106M−1min−1, koff (K2) to
0.05 min−1 and the concentration of the unlabelled
ligand (I) set to 15 nM (red squares), 50 nM (green triangles) and 150 nM (blue diamonds). For A, the kon (K3) was set to 1× 106M−1min−1 and koff (K4) to 0.05
min−1. For B the kon (K3) was set to 1×106M−1min−1 and koff (K4) to 0.01 min−1 thus demonstrating the classic tracer ‘overshoot’, observed when an unlabelled
ligand has a slower koff than the labelled ligand.
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2015). The use of elements such as terbium which have long-lived
fluorescence, allows for a time delay (50–150 μs) between excitation
and measurement of the resulting fluorescence from the donor and
acceptor. This reduces auto-fluorescence from other components within
the sample and improves signal to noise ratios. In the BRET metho-
dology, the receptor is tagged with the small, bright luciferase NanoLuc
which in the presence of its substrate furimazine produces biolumi-
nescent light (Hall et al., 2012). Then if in close enough proximity
(< 10 nm), the resonance energy from the NanoLuc can be transferred
to a fluorescent ligand bound to the receptor. The overall approach of
both energy transfer based techniques is similar to the classic compe-
titive association radioligand binding methodology described above,
except that a modified Motulsky and Mahan competitive binding model
is employed to take into account apparent bleaching of the fluorophore
in the TR-FRET method caused by laser excitation (Schiele et al., 2015).
The main advantage of RET techniques is that the signal recorded is
dependent on very close proximity between the two labelled species
and as a consequence is specific for the binding event between the la-
belled ligand and the tagged protein of interest. This means that se-
paration of bound and unbound label is no longer necessary and thus
this homogeneous assay format enables higher throughput (Emami-
Nemini et al., 2013). Due to the plate reader based format of RET as-
says, they can also achieve a greater kinetic resolution than radioligand
based techniques as reads can be made every 5 s if required. Both BRET
and TR-FRET techniques can be used with a range of fluorophores
making them compatible with the majority of fluorescent ligands
available for GPCRs. However an inherent limitation of RET techniques
is the need to label the receptor of interest using a exogenous substrate,
which potentially risks altering the receptor when compared to its
wildtype counterpart and can be a time consuming process. Never-
theless, RET techniques have been successfully applied to a variety of
GPCRs (Klein Herenbrink et al., 2016; Nederpelt et al., 2016; Stoddart
et al., 2015b) and to the receptor tyrosine kinase, vascular endothelial
growth factor receptor 2 (VEGFR2; Kilpatrick et al., 2017; Peach et al.,
2018) and have made the determinination of kinetics more attainable
for many researchers working with membrane bound receptors.
4. Factors that can influence binding kinetics
In addition to a direct molecular interaction of a ligand with the
orthosteric binding site of a receptor, there are many factors that can
influence the kinetics of ligand binding. As with any mathematical
equation, those used to analyse data obtained in kinetic experiments
require certain assumptions to be met in order that the models applied
are valid. In the following section, we will discuss the factors that can
change kinetic rates and how this may influence the assumptions we
make when fitting association and competition association experiments
(Fig. 5). The following examples are not exhaustive and there are other
factors such as ligand depletion (Carter et al., 2007; Hulme and
Trevethick, 2010), physiologically relevant ions (Katritch et al., 2014)
and direct effects of membrane lipids (Dawaliby et al., 2016; Bruzzese
et al., 2018) which are known to affect equilibrium binding parameters
but to date their influence on kinetic parameters have not been studied.
4.1. Single step binding
The process of ligand binding as described by the equations used to
formulate competition association binding models assumes that ligand
association and dissociation occurs in a single step (Fig. 5A, Motulsky
and Mahan, 1984). However molecular dynamic simulations, spectro-
scopy and crystallography all strongly suggest the presence of me-
tastable and/or intermediate states that occur during a multi step li-
gand-GPCR binding process (Fig. 5B, Latorraca et al., 2017). The
presence of such states along the binding pathway are likely to signal
what is referred to as a reduction in dimensionality, with the ligands
pathway trajectory into the binding pocket no longer controlled by the
Fig. 4. Schematic illustrating the principles of
bioluminescence resonance energy transfer
(BRET) and time resolved fluorescence resonance
energy transfer (FRET) to measure ligand binding
kinetics at G protein-coupled receptors (GPCRs).
In time resolved fluorescence resonance energy
transfer (TR-FRET) assays, lanthanides are used as
fluorescent donors as their long emission lifetimes
allow measurements to be made following a time
delay. This results in increased sensitivity as short-
lived background fluorescence is decreased allowing
TR-FRET to be used in situ. Here, a SNAP-Tag has
been engineered onto the N terminus of a GPCR of
interest, and the lanthanide donor (illustrated here
using terbium cryptate) is delivered to the receptor
via a membrane impermeant lanthanide labelled
SNAP-Tag substrate (1). The lanthanide label is then
excited using laser excitation (eg. ∼340 nm; yellow
lightning arrow). If the lanthanide and fluorescent
ligand are within close proximity (typically< 10
nm), the energy emitted following lanthanide ex-
citation can be transferred to excite the fluorophore
of the fluorescent ligand (FRET). Fluorescence
emissions from the donor and acceptor can be re-
corded and used to calculate subsequent FRET ratios.
For bioluminescence resonance energy transfer
(BRET) assays, a membrane bound receptor of in-
terest (eg. a G protein-coupled receptor (GPCR)), is tagged at its N terminus with a bioluminescent protein donor (eg. NanoLuc). The NanoLuc substrate furimazine is
then added for 10–15min and basal BRET measurements are recorded (1). The fluorescent ligand of interest (acceptor) is then added (2). If the fluorescent acceptor
and donor luciferase are in sufficiently close proximity (typically< 10 nm) then the energy emitted upon furimazine oxidation (in the form of photons) can be
transferred to excite the fluorophore of the fluorescent ligand (BRET). Luminescence and subsequent fluorescence emissions can be recorded and used to calculate
BRET ratios.
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laws of free diffusion (Axelrod and Wang, 1994). The consequence of
this will be a change in the ligand's overall measured association rate.
These metastable and/or intermediate states are likely to be the basis
for on-rate mediated subtype receptor selectivity. In such cases, mea-
sured on (and off-rates) are simply the net effect of transitions between
multiple conformational minima, and require a more sophisticated
treatment than a simple two state model (Tang et al., 2017). Similarly
off-rate mediated selectivity has been attributed to Coulombic repul-
sion, which occurs when two molecules of the same charge come into
close proximity. The slow off rate of tiotropium from the M3 receptor
has been suggested to be due to the presence of a positively charged
residue (K5237.32) above the exit channel which is thought to mediate
Coulombic repulsion between the positively charged ligand and this
residue which subsequently slows the exit of the ligand from the re-
ceptor. The absence of this charged residue from the closely related M2
receptor potentially contributes to tiotropium's faster association and
dissociation rates compared to the M3 receptor. Ultimately this feature
may explain why tiotropium shows comparable affinities for both
muscarinic receptor subtypes but exhibits kinetic selectivity for the M3
receptor (Tautermann et al., 2013,Sykes et al., 2012b).
4.2. Allosteric modulation
Allosteric regulators are molecules which bind to a site distinct to
that of the endogenous or orthosteric ligand and by definition alter the
binding kinetics of the orthosteric ligand (Christopoulos and Kenakin,
2002. Fig. 5C). Allosteric modulators can have varied effects on kinetic
parameters and can change association rates, dissociation rates or both
to the same or different degrees (Kostenis et al., 1996; Molderings et al.,
2000; Gao et al., 2001). Indeed, numerous examples of endogenous
substances acting as allosteric modulators of GPCRs have been de-
scribed (van der Westhuizen et al., 2015). Another important hallmark
of allosteric modulators is that they are probe dependent, which means
that they have varying effects depending on the orthosteric ligand used.
As with measuring the kinetics of orthosteric ligands, this means that
only the effects on a labelled molecule can be measured. To address
this, Guo et al. extended the use of the competition association assay to
investigate the effect of allosteric modulators at the adenosine A1R (Guo
et al., 2014). In this study, the radiolabelled antagonist ([3H]DPCPX)
was used to measure the kinetics of unlabelled orthosteric ligands in the
presence and absence of two different allosteric modulators. As the
equations used to analyse data obtained in competition association
assays requires the kon and koff of the labelled ligand to be fixed, the
authors directly measured the kinetics of [3H]DPCPX in the presence of
the two modulators and used these values in subsequent analysis. Im-
portantly they found that there was not a global change in the kinetic
constants of the labelled ligand ([3H]DPCPX) in the presence of the
probes therefore the effect of the modulators on the residence time of
other orthosteric compounds could be tested. It was found that the
modulators increased the residence time of the agonists CCPA and
Fig. 5. Schematic illustrating how ligand binding
kinetic association and dissociation rates can be
influenced by receptor and cellular factors. The
kinetics of ligand binding to its cognate receptor can
be defined in respect to its association rate (termed
the kon rate for that respective ligand; dashed black
arrows) and its dissociation rate into aqueous solu-
tion (termed the koff rate; dashed blue arrows).
Ligand binding can be a single step process (A), or
involve multiple steps whereby a ligand must in-
itially interact with a remote site on the receptor
prior to its slower access into the deeper orthosteric
binding site (B). Many membrane bound receptors,
such as GPCRs, contain additional allosteric sites
which are topographically distinct from that of the
orthosteric ligand binding site (C). If a secondary
ligand is bound to an allosteric site (ligand shown in
yellow), it has the potential to substantially mod-
ulate (increase or decrease) the association and/or
dissociation rates of the tracer ligand at the orthos-
teric site (yellow arrow). Ligands with high lipophi-
licity are often reported to interact with the lipid
bilayer in order to access the orthosteric ligand
binding site (D). Due to the potential requirement for
lateral diffusion through the bilayer, the association
rates measured in kinetic assays may not wholly re-
present the individual microkinetic events that
govern binding of these ligands. Local ligand con-
centrations above cells have been shown to be af-
fected by receptor concentration and cellular factors
such as interaction with the lipid bilayer and extra-
cellular matrix components such as heparan sulfate
proteoglycans (E). Ligand concentrations should
therefore not be assumed to be freely diffusing uni-
formly in solution, but may instead be concentrated
as gradients (red triangle) around receptors with the
potential to substantially alter association rates. A
further phenomenon that may affect measured ligand association and dissociation rates is drug-receptor rebinding (F). Here a reversibly bound ligand dissociates
according to the ‘effective’ reverse rate coefficient ((kr) dashed green arrows)) from its cognate receptor but is then able to rebind to the same or a nearby receptor
according to the ‘effective’ forward rate coefficient ((kf) dashed red arrows) before diffusing away into bulk aqueous solution. The rebinding process is favored by
ligands with ‘fast’ association kinetics and is influenced by the diffusion rate of the ligand, receptor expression levels and localised restrictions on free ligand diffusion
(eg. Local receptor compartment geometry, with contributions from the lipid bilayer and extracellular matrix components).
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NECA which demonstrated both the probe dependence of the mod-
ulators and that subtle differences could be measured using this
methodology. The competition association assay has also recently been
used to directly measure the kinetics of allosteric modulators at the
metabolic glutamate receptor 2 (Doornbos et al 2017, 2018). As men-
tioned above as one of the main characteristics of allosteric modulators
is that they change either the association or dissociation rates of an
orthosteric ligand applying the Motulsky Mahan equation to data ob-
tained using an allosteric modulator needs to be done with caution.
Allosteric modulation of a GPCR does not necessarily need to be by a
small molecule, it can also be through interaction with accessory pro-
teins such as G protein and β-arrestins or through dimerization with
another GPCR. This has been demonstrated to be the case for the ade-
nosine A3 receptor and the β1 adrenoceptor (May et al., 2011; Gherbi
et al., 2015). For the adenosine A3 receptor it was shown that orthos-
teric ligands enhanced the dissociation rate of a labelled agonist.
Through the use of a non-binding mutant of the receptor, it was shown
that this effect was due to allosteric modulation across a homodimeric
interface (May et al., 2011).
4.3. Local ligand concentration and ligand interaction with plasma
membrane
One of the main assumptions made in the equations used to analyse
kinetic binding experiments is that the ligands are freely diffusing in
solution (Fig. 5E). A recent study by Gherbi et al. shed light on the
phenomenon of local ligand concentration (Gherbi et al., 2018). Using a
fluorescent ligand for the β2-adrenoceptor (β2-AR), BY-propranolol, in
combination with the sensitive microscopy technique fluorescence
correlation spectroscopy (Briddon et al., 2017) they were able to
quantify the local concentration of fluorescent ligand at different dis-
tances from the plasma membrane. They found that the concentration
of BY-propranolol increased the closer to the membrane the measure-
ments were made. Crucially they found that this was dependent on the
expression of the β2-AR, with double the concentration observed in β2-
AR expressing cells compared to non-transfected cells. The equations
used to calculate affinity from both equilibrium and kinetic experiments
requires knowledge of the free concentration of the labelled ligand
used. The analysis also assumes that the concentrations of both labelled
and competing ligand are constant and not changed by ligand-binding
to the receptor or proximity to the receptor. Consequently if the local
concentration is higher than the bulk added concentration then this will
lead to an apparent overestimation of affinity. For the β2-AR, using the
concentration determined closest to the membrane the affinity of BY-
propranolol was 25-fold lower than that calculated with the bulk added
concentration (Gherbi et al., 2018). Although technically challenging,
this study highlights the need to consider the influence of the local
concentration of ligand when determining binding kinetics and that
receptors expressed in different cells and at different expression levels
may also affect the concentration of a specific ligand.
In addition to non-uniform distribution of ligands in aqueous solu-
tion, ligands can interact directly with the lipids in the plasma mem-
brane thus altering their diffusion characteristics and potentially con-
centrating them around a particular receptor (Vauquelin and Packeu,
2009, Fig. 5D). This has been studied extensively for the β2AR to un-
derstand a question which has perplexed pharmacologists for the past
20 year or so as to why certain agonists for this receptor are so long
acting (Anderson et al., 1994; Sykes and Charlton, 2012). Calculating
lipophilicity (logP) from the structure of a molecule is the easiest way to
estimate the propensity of a molecule to interact with the lipophilic cell
membrane. It has been demonstrated for a variety of ligands that this
has particular relevance to receptors where the native ligand is thought
to enter the binding pocket via lateral diffusion through the plasma
membrane (Fig. 5D). Receptors that have been proposed to utilise this
route of entry include the sphingosine-1-phosphate receptor 1 (S1P1,
for which a crystal structure is available), opsin and cannabinoid re-
ceptors (Hanson et al., 2012; Hildebrand et al., 2009; Hurst et al.,
2010). More recently a lipid pathway has been proposed for small
molecules binding to the peptide activated receptor PAR1 (Bokoch
et al., 2018). Kinetic association parameters for the native ligands have
not been measured directly for these receptors and it is entirely possible
that the microkinetic parameters may differ from measured parameters
due to this process of lateral diffusion.
4.4. Rebinding
Drug-receptor rebinding occurs in situations where free diffusion is
limited and describes the process whereby a reversibly bound com-
pound rebinds to the same or nearby receptor before diffusing away
into bulk aqueous solution (Fig. 5F). Rebinding has been the topic of a
number of recent and insightful reviews (Vauquelin 2010, 2016; de
Witte et al., 2016, 2017). As such, drugs may be thought to possess an
‘intrinsic on-rate’ which will potentially differ from their ‘measured on-
rate’ which is dictated by factors thought to influence the free con-
centration of a drug immediately surrounding the receptor's orthosteric
binding pocket as described in section 5.3 (Sykes et al., 2014a; Gherbi
et al., 2018).
Rebinding is characterised by the establishment of a new dynamic
equilibrium between the free target and freshly dissociated drug mo-
lecules with kon and koff being replaced by the forward (kf) and reverse
(kr) rate coefficients of binding (Fig. 5F). Normally when the conditions
of free diffusion operate a molecule dissociates according to its dis-
sociation rate constant (or koff) and it is assumed to simply drift away
into bulk aqueous. In contrast when rebinding predominates a drug
molecule will undergo multiple encounters with the initial target or
nearby receptors in accordance with the estimated effective reverse rate
coefficient (kr) (Vauquelin and Charlton, 2010). kr like koff is char-
acteristic of a particular ligand but the calculation of kr which is si-
tuation-dependent takes into account the unique tissue microenviron-
ment of the synapse and integrates both the association and dissociation
rate constants to calculate the overall rate of reversal of receptor
blockade.
The clinical relevance of this rebinding phenomenon has recently
been demonstrated through studying the in vitro kinetics of clinically
used antipsychotics and relating their measured on-rates to their pro-
longed receptor occupancy in vivo (Sykes et al., 2017; Seeman, 2002).
Specifically this study was able to demonstrate that the estimated ef-
fective reverse rate coefficient (or kr) of antipsychotics and not their koff
better predicts the levels of extrapyramidal side effects observed in
patients. Some useful in vitro systems have been proposed to gain some
understanding of this rebinding phenomenon (Spivak et al., 2006) but
‘micro-anatomical elements’ found only in intact tissue are a pre-
requisite if the in vivo situation is to be truly simulated (Vauquelin,
2010).
Rebinding of ligands is likely to play a role in extending the effects
of a drug in situations where high receptor densities are found, and
diffusion restriction imposed by the local geometry and composition of
the surrounding tissue. The synapse is an extreme example and re-
presents a semi-closed structure which is thought to be responsible for
extending the receptor occupancy of antipsychotics, and possibly other
centrally acting compounds (Vauquelin, 2010; Sykes et al., 2017).
4.5. Intact cell environment
There has been much debate around the use of membranes versus
intact or whole cells to study the binding kinetics of drugs (Motulsky
et al., 1985, Verheijen et al., 2004; Vauquelin et al., 2015; Sykes and
Charlton, 2018). It can be argued that membranes offer the opportunity
D.A. Sykes, et al. Molecular and Cellular Endocrinology 485 (2019) 9–19
14
to study drug-receptor interactions in a single compartment model
which is the situation the equations used to determine binding kinetics
were originally formulated for. Therefore any such measurements
should be free from many of the complications attributed to in-
accessible receptor compartments. This situation will be particularly
relevant in a competition association binding assay and be potentially
exacerbated if the tracer and competitor have vastly different physico-
chemical properties. Equally whole cells offer the opportunity to ob-
serve physiologically relevant information and may permit a better
understanding of the complex drug-target interactions and the potential
of complex kinetic binding phenomenon such as ‘rebinding’ to con-
tribute to extended receptor coverage that is not predicted by simple
one compartment models (Spivak et al., 2006; Vauquelin et al., 2015).
The ternary complex model for GPCR activation by agonists in-
dicates that the receptor-G protein complex has higher affinity for
agonists than receptor alone (De Lean et al., 1980). In the whole cell
environment, this agonist-receptor-G protein complex is short lived due
to the high intracellular concentration of GTP. Depending on the
method used for membrane preparation the concentration of GTP may
be low. This would promote a more stable complex of agonist-receptor-
G protein as there is minimal GTP present to induce separation of this
complex. It is worth noting, however, that homogenates prepared from
guinea pig cerebral cortex have been shown to contain vesicles that can
maintain a membrane potential (Creveling and McCulloh, 1980;
Creveling et al., 1983). This indicates that membrane preparations,
unless prepared in hypotonic media in the presence of detergent, will
consist of vesicles that could contain high concentrations of GTP.
Therefore, it must be emphasised that if agonist-receptor binding ki-
netics are studied in membranes using the Motulsky-Mahan model then
it is important to study these in the presence of GTP or better still stable
analogues of GTP such as GTPγS or GppNHp and a detergent to disrupt
vesicles. Studies into the kinetic parameters of agonists binding to the
muscarinic M3 receptor and the adenosine A1 receptor have been car-
ried out in the presence of GTP to promote G protein uncoupling (Sykes
et al., 2009; Xia et al., 2016). Kinetic parameters of an agonist (NECA)
binding to the adenosine A2A receptor were found to be unchanged in
the presence or absence of GTP (Guo et al., 2012) whereas for the
adenosine A3 receptor it was found that the presence of GTP did not
change the association rate constant for agonists but did have an effect
on the dissociation rate constants (Xia et al., 2018). Determining kinetic
rates in the presence and absence of GTP is likely to become increas-
ingly more important as fluorescent tracers with agonist-like properties
become more widely available for the study of unlabelled compound
kinetics (Klein-Herenbrink et al., 2016; Sykes et al., 2017).
The intact cell environment also maintains the native membrane
potential that a GPCR is normally subjected to. A number of GPCRs
have been shown to be voltage sensitive and that voltage can alter
agonist affinity (Mahaut-Smith and Gurung, 2008; Vickery et al., 2016).
One study has demonstrated that voltage can alter the kinetics of
muscarinic agonist binding (Ben Chaim et al., 2013). This study re-
quired the use of Xenopus oocytes to enable the effect of depolarization
to be investigated. Membrane potential is an important physiological
control in situations such as at the neuronal synapse and therefore
should be a consideration for GPCRs which are expressed in these
systems.
5. Moving towards understanding receptor kinetics at the
molecular level
5.1. Drug-receptor dissociation
With the advent of more high-throughput assays and an increased
interest in determining binding kinetics at GPCRs, larger data sets at a
range of receptors are becoming available. This, coupled with the
recent explosion of GPCR structural information, raises the possibility
of designing drugs that may drive a clinically favourable kinetic para-
meter. To do this it is important to understand the factors that may
influence specific kinetic properties to more accurately predict struc-
ture kinetic relationships (SKR). However, in truth, little is currently
known about the structural factors governing the kinetics of molecular
recognition.
There are many factors that have been proposed to influence drug-
receptor dissocation. It has been suggested that the presence of water
shielded hydrogen bonds may be responsible for slow dissociation of
certain compounds essentially acting as ‘kinetic traps’ which effectively
increase the stability of the drug receptor complex. This effect is pro-
posed to be partly responsible for the slow rate of dissociation of the
long acting muscarinic antagonist tiotropium (Tautermann, 2016). This
occurs when rupture of shielded hydrogen bonds transpires at slower
rates due to these hydrogen bonds being essentially protected from the
effects of water (Schmidtke et al., 2011). Similar observations have
proposed that the displacement of unfavourable water molecules in the
binding pocket may provide a plausible explanation for slow dissocia-
tion of certain antagonists from the cannabinoid CB1 receptor (Xia
et al., 2017). High resolution structural information has led to specific
structural features of receptors being suggested to control dissociation
of drugs from receptors. For example the residence times of ligands at
the adenosine A2A receptor has been shown to correlate with the energy
required to break a salt bridge found at the entrance to the A2A receptor
orthosteric binding site (Segala et al., 2016). At this receptor, long re-
sidence time ligands appear to stabilize the Glu−His ionic interaction,
while fast off-rate derivatives were generally predicted to destabilize
this salt bridge. Others have suggested that structural movements of
both receptor and or ligand may both hinder association rates and
concurrently promote slow dissociation rates (Cusack et al., 2015; Buil
et al., 2016). In such a scenario the receptor must first change con-
formation before a particular ligand is able to recognise and bind the
receptor. Such a mechanism has been observed with the low affinity
slowly associating/dissociating protease activated receptor 2 specific
allosteric ligand AZ8838. In this example ligand entry and exit simu-
lations suggest that rotation of the side chain of His227ECL2 is required
to facilitate ligand entry/release through the orthosteric pocket (Cheng
et al., 2017). It is likely that dissociation is a combination of many of
the above factors. Further molecular and pharmacological studies will
lead to a greater understanding of the dissociation process and how to
dial in the required dissociation constant.
Rather than specific interactions that a molecule makes at the mo-
lecular level, it may be that more general physicochemical properties of
a ligand could go some way to predict kinetic rate constants. Molecular
weight, lipophilicity (clogP) and rotational bonds have all been pro-
posed to affect residence time (Miler et al., 2012). As more GPCR
structural information becomes available it may become routinely
possible to explore the number of close contact residues a particular
compound makes within the binding pocket. To illustrate the potential
impact of this, we have taken kinetic data for the β2AR (Sykes et al.,
2014) and correlated koff with the number of close contact residues each
of these compounds is predicted to make from molecular modelling
(Audet and Bouvier, 2008; Warne et al., 2008). The number of close
contact residues correlates well with the measured off-rates of eight
β2AR specific compounds for which close contact information is avail-
able (Fig. 6A). Interestingly the heavy atom count (HAC), which is an
indicator of increasing molecular weight, was not correlated with koff
emphasising that residence time (1/koff) is perhaps more about the
quality of interactions made by the ligands in the binding pocket rather
than just a general increase in the bulk of a particular molecule
(Fig. 6B). With ever increasing numbers of large data sets and high
resolution structural information, it is likely that it will become easier
to predict kinetics parameters for a given molecule.
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5.2. Drug-receptor association and its role in pharmacodynamics
The association process has received much less attention than the
dissociation binding step as a factor important in the pharmacodynamic
(PD) properties of drugs. However evidence is slowly emerging to
suggest that the measured association rate may be just as important as
the dissociation rate of a drug in determining the overall PD properties
of drugs (de Witte et al., 2016). Until recently it was thought that
molecules within a chemical series would share very similar association
rates and that affinity (or Kd) changes were driven mainly by changes in
the magnitude of the dissociation rate (Tummino and Copeland 2008;
Núñez S et al., 2012). However, there are many examples where rela-
tively minor changes in structure lead to a significant change in the
magnitude of kon, and therefore directly to a change in affinity (Guo
et al., 2012; Sykes et al., 2014). Factors which are thought to affect the
association process include diffusion, desolvation and the molecular
orientation of the molecule (Copeland et al., 2006; Núñez S et al., 2012;
Pan et al., 2013). Theoretically, drugs with non-polar substituents, thus
making them more lipophilic, should find it easier to lose and displace
water on entry to the binding pocket. This may partly explain the
propensity for lipophilic compounds to show increased measured on-
rates (Sykes et al., 2014). Such a scenario is also supported by mole-
cular dynamic studies of the β2AR which showed that ligand association
is affected by the ease with which ligands lose their associated water
shells (so called dewetting) and evacuate it from the ligand binding
pocket (Dror et al., 2011) with water acting essentially as a barrier to
successful ligand binding. This is also supported by studies on heat
shock protein (HSP90), where polar substituents were introduced on to
molecules to slow binding association (Schuetz et al., 2018). Apart from
the introduction of polar groups it may also be possible to introduce
groups that create steric clashes within the binding pocket as a me-
chanism of introducing on-rate driven receptor selectivity (Spagnuolo
et al., 2017).
In theory drugs with higher molecular mass should show reduced
rates of association due to limited access to the binding pocket through
what is effectively a narrow passageway (Pan et al., 2013). We have
taken data from published studies describing the on-rates of antagonists
for the serotonin receptor 2B (5HT2B) and investigated if there is any
correlation with heavy atom count (HAC) (Fig. 7; Unett et al., 2013;
Wacker et al., 2017). In this example we see how increasing 5HT2B
ligand HAC results in a gradual reduction in the measured on-rates of
these compounds. Specifically why this should be the case is open to
speculation but it is accepted that the 5HT2B receptor possess a ‘lid’
formed by extracellular loop 2 (EL2) residues 207–214 at the entrance
to the binding pocket (Wacker et al., 2017). This ‘lid’ effectively covers
the binding pocket and may severely restrict the entry and exit of larger
molecules. In contrast β2AR ligand HAC was not correlated with
changes in association rate emphasising the seemingly receptor specific
effect of HAC observed with ligands at the 5HT2B receptor. The de-
terminants and importance of association rate are only starting to be
uncovered and recognising that both kon and koff kinetic parameters
play a role will lead to a greater understanding of in vivo drug action.
Fig. 6. Correlating β2 adrenergic ligand kinetic
properties with number of close contact residues
and heavy atom count (HAC). Correlation plot
showing the relationship between β2 adrenergic
compound (A) log koff and the number of close con-
tact residues in the orthosteric binding pocket, (B)
log koff and the physicochemical property HAC.
Kinetic data are presented as mean from three or
more experiments. Close contact residue information
is taken from Audet and Bouvier (2008) and Warne
et al. (2008). All kinetic data used in these plots are
detailed in Sykes et al. (2014). Physicochemical
properties data was obtained from the National
Center for Biotechnology Information. PubChem
Compound Database; https://pubchem.ncbi.nlm.nih.
gov/compound/. Data was analysed using linear re-
gression in GraphPad Prism v.7 and the relationship
between two variables was assessed using a two-
tailed Spearman's rank correlation allowing the cal-
culation of the correlation coefficient, rs. A P value of
0.05 was used as the cutoff for statistical significance
and relationships depicted as trend lines.
Fig. 7. Correlating 5HT2B and β2AR ligand heavy
atom count (HAC) with the measured rate of as-
sociation (kon). Kinetic data are presented as mean
values. All 5HT2B kinetic data used in these plots are
detailed in Unett et al. (2013) and Wacker et al.
(2017). β2AR ligand kinetic data used in these plots
are detailed in Sykes et al. (2014) Physicochemical
properties data were obtained from the National
Center for Biotechnology Information. PubChem
Compound Database; https://pubchem.ncbi.nlm.nih.
gov/compound/. Data was analysed using linear re-
gression in GraphPad Prism v.7 and the relationship
between two variables was assessed using a two-
tailed Spearman's rank correlation allowing the cal-
culation of the correlation coefficient, rs. A P value of
0.05 was used as the cutoff for statistical significance
and relationships depicted as trend lines.
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In addition, the majority of the studies discussed in this section use
synthetic labelled and unlabelled compounds. Endogenous ligands for
family A GPCRs of the amine variety tend to show fast on and off-rates
(Sykes et al., 2009; Sykes et al., 2012; Klein-Herenbrink et al., 2016)
which has made them particularly challenging to measure under phy-
siological conditions. The development of TR-FRET and BRET based
methodologies with increased kinetic resolution will aid in the accurate
determination of the kinetics of a range of endogenous ligands for fa-
mily A GPCRs. As concentrations of endogenous ligands can fluctuate
widely, especially during synaptic transmission, small changes in oc-
cupancy influenced by the koff of the competing drug, may still allow
enough endogenous ligand to bind and elicit a functional response
(Vauquelin et al., 2012). Therefore, when determining the influence of
binding kinetics on the efficacy of pharmacologically active compounds
in vivo, it is important to also understand the kinetics of any competing
endogenous ligand and the physiological context under which potential
competition occurs.
5.3. Concluding remarks
In the last ten years there have been huge advances in studying and
understanding the importance of binding kinetics at GPCRs.
Determining binding kinetics should be central to all drug discovery
efforts and with the ever increasing number of GPCR structures and
kinetic data sets it should be possible to gain a fuller picture of the
molecular determinants of association and dissociation rates. This effort
into understanding binding kinetics will in turn help to inform the latest
pharmacodynamic models which can be used to predict therapeutic
drug actions in vivo based partly on their in vitro kinetic profiles (Boger
et al., 2016; Mager and Krzyzanski 2005; Vlot et al., 2017). Such
knowledge has the potential to enhance drug discovery processes and
ultimately give rise to new therapeutics with improved properties.
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